Ad is loading...
PABFX
Price
$18.73
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
RLEFX
Price
$36.39
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
Ad is loading...

PABFX vs RLEFX

Header iconPABFX vs RLEFX Comparison
Open Charts PABFX vs RLEFXBanner chart's image
PGIM Balanced Z
Price$18.73
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
American Funds American Balanced R5E
Price$36.39
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
PABFX vs RLEFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
PABFX vs. RLEFX commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PABFX is a Buy and RLEFX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RLEFX has more cash in the bank: 237B vs. PABFX (1.02B). RLEFX (2.42) and PABFX (2.31) have matching dividends . PABFX was incepted earlier than RLEFX: PABFX (32 years) vs RLEFX (9 years). RLEFX is a more actively managed with annual turnover of: 171.00 vs. PABFX (141.00). PABFX has a lower initial minimum investment than RLEFX: PABFX (0) vs RLEFX (250). RLEFX (21.00) and PABFX (20.03) have marching annual gain over last year. RLEFX return over 5 years is better than : 37.39 vs. PABFX (25.08).
PABFXRLEFXPABFX / RLEFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence32 years9 years-
Gain YTD13.86215.09792%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets1.02B237B0%
Annual Yield % from dividends2.312.4296%
Returns for 1 year20.0321.0095%
Returns for 3 years0.6412.545%
Returns for 5 years25.0837.3967%
Returns for 10 years27.65N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PUBM16.200.95
+6.23%
PubMatic
TPG69.702.14
+3.17%
TPG
DM4.400.06
+1.38%
Desktop Metal
FLUT266.723.35
+1.27%
Flutter Entertainment plc
ESLA0.89-0.03
-3.31%
Estrella Immunopharma